Development of an inducible anti-VEGF rAAV gene therapy strategy for the treatment of wet AMD

Vascular endothelial growth factor (VEGF) is a key mediator in the development and progression of choroidal neovascularization (CNV) in patients with wet age-related macular degeneration (AMD). As a consequence, current treatment strategies typically focus on the administration of anti-VEGF agents,...

Descripción completa

Detalles Bibliográficos
Autores principales: Reid, Christopher A., Nettesheim, Emily R., Connor, Thomas B., Lipinski, Daniel M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6079038/
https://www.ncbi.nlm.nih.gov/pubmed/30082848
http://dx.doi.org/10.1038/s41598-018-29726-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6079038/
https://www.ncbi.nlm.nih.gov/pubmed/30082848
http://dx.doi.org/10.1038/s41598-018-29726-7

Ejemplares similares